Gain-of-function polymorphism in mouse and human Ltk: implications for the pathogenesis of systemic lupus erythematosus

Authors:
  • KNKazuhiro Nakamura
    Kazuhiro Nakamura
  • YJYi Jiang
    Yi Jiang
  • HTHiromichi Tsurui
    Hiromichi Tsurui
  • SMShuji Matsuoka
    Shuji Matsuoka
  • MAMasaaki Abe
    Masaaki Abe
  • MOMareki Ohtsuji
    Mareki Ohtsuji
  • HNHiroyuki Nishimura
    Hiroyuki Nishimura
  • KKKiyoshi Kato
    Kiyoshi Kato
  • TKTakako Kawai
    Takako Kawai
  • TATatsuya Atsumi
    Tatsuya Atsumi
  • TKTakao Koike
    Takao Koike

Abstract
Systemic lupus erythematosus (SLE), a complex multigenic disease, is a typical antibody-mediated autoimmune disease characterized by production of autoantibodies against a variety of autoantigens and immune complex-type tissue inflammation, most prominently in the kidney. Evidence suggests that genetic factors predisposing to aberrant proliferation/maturation of self-reactive B cells initiate and propagate the disease. In SLE-prone New Zealand Black (NZB) mice and their F1 cross with New Zealand White (NZW) mice, B cell abnormalities can be ascribed mainly to self-reactive CD5+ B1 cells. Our genome-wide scans to search for susceptibility genes for aberrant activation of B1 cells in these mice showed evidence that the gene, Ltk, encoding leukocyte tyrosine kinase (LTK), is a possible candidate. LTK is a receptor-type protein tyrosine kinase, belonging to the insulin receptor superfamily, and is mainly expressed in B lymphocyte precursors and neuronal tissues. Sequence and functional analyses of the gene revealed that NZB has a gain-of-function polymorphism in the LTK kinase domain near YXXM, a binding motif of the p85 subunit of phosphatidylinositol 3-kinase (PI3K). SLE patients also had this type of Ltk polymorphism with a significantly higher frequency compared with the healthy controls. Our findings suggest that these polymorphic LTKs cause up-regulation of the PI3K pathway and possibly form one genetic component of susceptibility to abnormal proliferation of self-reactive B cells in SLE.